February 2026 Research Update

This month, the treatment studies reinforced a consistent message: patients who reach deeper control of the abnormal light-chain producing cells tend to do better, and modern anti-plasma cell combinations can achieve strong blood and organ responses in routine care. A real-world study of daratumumab with bortezomib and dexamethasone reported high rates of deep blood responses along with early heart, kidney, and liver responses, including people with advanced cardiac stage. Across separate cohorts, survival remained strongly shaped by how severe heart involvement is at the start, and by how deep the blood response becomes over time. [1] [2]

One study focused on daratumumab plus bortezomib and dexamethasone (DVD), a daratumumab-based combination, and reported that many patients achieved complete response or very good partial response, with organ responses seen by 6 months and manageable toxicity reported. The same report noted worse survival in the most advanced cardiac stage compared with a slightly less advanced stage, emphasizing that cardiac severity still matters even with active therapy. This adds real-world context for what patients might expect from a daratumumab-based regimen outside of a clinical trial. [1]

A larger cohort of patients treated with bortezomib-based chemotherapy reported that deep blood responses were common and that deeper response at 6 months was linked to longer overall survival. In that cohort, advanced cardiac involvement, older age, and autonomic nerve problems were tied to poorer survival, highlighting that both organ involvement and response depth affect the long-term picture. Taken together with the DVD study, this month strengthens the idea that treatment success is not only about starting a regimen, but also about achieving a strong light-chain response and managing advanced organ disease. [2]

Two other treatment-focused studies addressed how care differs across patient groups and settings. A large registry analysis found that common phase III trial eligibility rules would exclude many real-world patients, and those excluded had lower blood response rates and much shorter survival, largely because they had more severe heart disease, worse overall function, or poor kidney function. Separately, a U.S. clinician survey about plasma cell disorders in kidney transplant settings found wide variation in management approaches and that only a minority of centers reported having formal protocols, reflecting ongoing uncertainty in this area of care. [3] [4]

This month also revisited two specialized areas of treatment: stem cell transplant consolidation and cardiac devices. A single-center comparison reported longer survival for people who underwent high-dose chemotherapy with autologous stem cell transplant (HDCT/ASCT) than for those who received chemoimmunotherapy alone, including within subgroups defined by daratumumab use, while acknowledging that the transplant group started out healthier in several ways. A national inpatient database analysis reported that people with AL amyloidosis who received pacemakers or defibrillators had higher in-hospital mortality than those with ATTR amyloidosis receiving similar devices, and tended to stay in the hospital longer, underscoring how fragile some hospitalized AL patients can be around procedures. [5] [6]

Finally, one imaging follow-up study in AL cardiac amyloidosis suggested that heart muscle imaging measurements can improve over about 12 months after anti-plasma cell therapy, especially in people who achieved a strong blood response or a cardiac response. The reported changes included reduced measures related to tissue abnormality and improved pumping-related measures, with a hint of continued improvement in a smaller longer-followed group. This helps connect blood response with measurable changes in the heart over time, although it does not prove that imaging changes will occur for every patient. [7]

For patients and caregivers, this month adds clarity that treatment results often track with two things: how advanced organ involvement is at diagnosis (especially the heart) and how deep the light-chain response becomes after therapy. The strongest evidence here comes from moderate-strength cohort and registry studies, which can describe patterns but cannot fully separate treatment effects from differences in who received which therapy. The trial-eligibility registry work also helps explain why outcomes in everyday care can look different from trial results, because many people with the highest-risk features would not qualify for typical frontline trials. Important uncertainties remain about which approaches work best for the sickest patients and how best to standardize care in complex situations like kidney transplantation. [1] [2] [3] [4] [5] [7] [6]

This month, multiple studies converged on a practical point: getting the amyloid type right, and getting to that answer sooner, remains a major challenge that can change the entire care path. Real-world and patient-reported data both showed that delays and multiple visits are common before AL amyloidosis is confirmed [8] [9] . Other reports showed how standard tests can be inconclusive, and how tissue typing, mass spectrometry, and genetic testing help resolve ambiguous cases and avoid misclassification [10] [11] [12] .

Two studies described diagnostic delays from different angles and landed on a similar story. In a Japanese claims-database analysis of adults diagnosed with AL amyloidosis, the median time from first hospital visit to confirmed diagnosis was 81.5 days, with longer delays in older people and those with more other health problems, and shorter time when hematology was involved early. In a U.S. patient survey, many people reported delays, commonly saw several providers before diagnosis, and often felt delays were due to limited awareness, helping explain why early symptoms can be missed or attributed to more common conditions. [8] [9]

Several reports highlighted that tissue typing methods and careful subtyping are central when results are ambiguous. A consensus document reviewed biopsy-based approaches for typing cardiac amyloid and compared methods such as immunostaining and mass spectrometry, emphasizing that tissue confirmation remains fundamental for many patients. Supporting that message, one kidney case showed an initial AL diagnosis that later proved to be a hereditary fibrinogen amyloidosis after genetic testing, and the report stressed that mass spectrometry and genetics can be important when standard staining is unclear. [10] [11]

This month also included early, single-patient examples of how additional testing can resolve confusing clinical pictures. One cardiac case used a specialized PET/CT scan (68Ga-FAPI-46) after prior imaging and biopsies were inconclusive, which then prompted a repeat bone marrow biopsy that confirmed AL amyloidosis. Another case with cardiac and nerve symptoms initially raised concern for AL, but genetic testing ultimately identified an inherited transthyretin (TTR) variant, showing how a person can appear to fit one amyloid type while actually having another. [13] [12]

Finally, two reports broadened the diagnostic story to less typical organ presentations and overlapping kidney diseases. A gastric case showed amyloid in stomach tissue after it had been mistaken for more common gastritis, with the authors suggesting certain endoscopy patterns might raise suspicion while confirming that Congo red staining is still essential. A small case series described early membranous nephropathy occurring alongside several different kidney amyloid types, underscoring that more than one kidney problem can be present and that exact pathology classification matters for understanding prognosis. [14] [15]

One study addressed diagnosis from a health-systems perspective by testing how reliable registry codes are. In Denmark, amyloidosis diagnosis codes had a high positive predictive value overall and for AL specifically, while coding accuracy was lower for inherited ATTR due to small numbers and subtype complexity. This matters for patients because high-quality registries can support better research and planning, but it also shows that subtype labeling can be harder to capture reliably outside of detailed medical records. [16]

For patients, this theme mainly adds understanding rather than changing anything immediately: delays and occasional mis-typing are common, and multiple data sources this month showed why. The strongest message is that amyloidosis is not one disease, and accurate typing sometimes requires more than one step, especially when initial biopsies or scans do not fit neatly. The evidence ranges from database and survey studies (useful for showing patterns) to case reports (useful for illustrating pitfalls but not predicting what will happen for others) and a consensus review. What remains uncertain is which combinations of tests most reliably shorten time to a correct diagnosis across different healthcare settings, and how broadly newer tools will help beyond individual examples. [8] [9] [10] [11] [13] [12] [14] [15] [16]

This month, prognosis studies sharpened a familiar but important picture: outcomes in AL amyloidosis are strongly influenced by heart involvement and by markers of how large or active the plasma cell disorder is. Across different settings, higher bone marrow plasma cell burden and coexisting multiple myeloma were repeatedly linked to poorer survival [17] [18] , and kidney-focused data highlighted how cardiac involvement can also shape kidney outcomes and mortality [19] . A separate meta-analysis in cardiac amyloidosis (AL and ATTR) suggested that certain left atrial function measurements may add prognostic information, but the certainty of that evidence was low. [20]

Two studies aligned on bone marrow plasma cell percentage as a meaningful risk marker. A systematic review pooling 10 studies found that having 10% or more plasma cells in the bone marrow was linked to worse overall survival and progression-free survival, although results varied across studies and there were signs of publication bias. Separately, a single-center cohort found poorer survival when bone marrow plasma cells were higher and when multiple myeloma was present, along with additional risk linked to heart failure and an elevated blood clot-breakdown marker. [18] [17]

Kidney-centered data this month added detail about how AL-related kidney disease can behave among broader monoclonal-protein kidney disorders. In a cohort of biopsy-confirmed monoclonal gammopathy of renal significance (MGRS), most cases were renal amyloidosis, and the amyloidosis group had worse kidney survival than non-amyloid MGRS. Within that study, achieving blood response and kidney response went together with longer survival, while hypertension, higher creatinine, and cardiac involvement were among predictors of kidney failure, and cardiac involvement and age predicted mortality. [19]

Two meta-analyses focused on cardiac risk, one in mixed amyloidosis types and one in multiple myeloma with cardiac AL. In cardiac amyloidosis overall (AL and ATTR), lower left atrial reservoir strain and related measures were linked to higher risk of death and atrial fibrillation, but the authors rated the certainty as low or very low and did not support routine prognostic use yet. In multiple myeloma, having concomitant cardiac AL amyloidosis was linked to higher mortality at several timepoints than not having cardiac involvement, reinforcing how powerful cardiac involvement can be as a driver of outcomes. [20] [21]

For patients and caregivers, this theme helps explain why people with AL amyloidosis can have very different courses even when they share the same diagnosis. The most consistent signals this month were that heavier bone marrow plasma cell involvement, coexisting multiple myeloma, and heart involvement tend to go along with shorter survival, while better blood and kidney responses tend to go along with longer survival in kidney cohorts. Some newer imaging-based heart measurements may become helpful for risk prediction in the future, but the evidence was rated low certainty and is not yet a settled part of prognosis. These studies are about understanding patterns and risk signals, not about predicting an individual person's outcome from a single test. [18] [17] [19] [20] [21]

This month’s case reports mostly served as reminders of how varied amyloidosis can look, and how a single symptom can lead down very different diagnostic paths. Several cases showed that unusual organ involvement or confusing test results can delay the correct amyloid type classification, while a few highlighted that modern anti-plasma cell therapy can still produce meaningful improvement even in uncommon presentations. As individual stories, these reports cannot predict what will happen for others, but together they map out common pitfalls and rare scenarios. [22] [23]

Two cases emphasized less typical organ presentations and how diagnosis was ultimately confirmed by tissue evidence. One patient presented with pleural effusion, and diagnosis was made through thoracoscopy with pleural biopsy showing amyloid, followed by reported clinical and imaging improvement after therapy. Another patient had stomach involvement initially mistaken for Helicobacter pylori-related gastritis, with later Congo red-positive biopsy confirming amyloid and subsequent recognition of systemic disease. [23] [14]

One case illustrated hepatic-predominant systemic AL amyloidosis occurring alongside multiple myeloma, with severe jaundice and enlarged liver. After daratumumab plus cyclophosphamide, bortezomib, and dexamethasone (Dara-VCD), the report described a very good partial blood response and substantial improvement in liver tests, although serious infections required temporary treatment interruption. This case adds an example of potential responsiveness in a rare presentation, alongside a reminder that infections can occur during therapy. [22]

For patients, the value of these case reports is mostly in awareness: amyloidosis can show up in unexpected ways, and confirmation often relies on getting the right tissue sample and staining. The improvement described after therapy in pleural and hepatic presentations shows what can be possible in individual situations, but these are single-patient experiences and may not apply broadly. What remains uncertain is how often these uncommon presentations occur and which diagnostic steps are most efficient in routine practice, since case reports do not measure that. [23] [14] [22]

One small, early study this month looked at amyloid at the molecular level and suggested that not all light-chain amyloid fibrils look the same across diseases. Using fat biopsy samples from two living people with multiple myeloma, researchers identified several fibril shapes that differed from those reported in AL amyloidosis, raising the possibility that light-chain aggregation may happen through different mechanisms in different settings. This is laboratory-focused research and does not yet translate into patient outcomes, but it adds a clearer picture of biological diversity. [24]

For patients, this is mainly future-facing research: it does not change diagnosis or treatment now, but it helps explain why amyloid diseases can behave differently. By showing structural differences in fibrils from living patients, this line of work may eventually support better tests or more tailored approaches if confirmed in larger groups. What remains uncertain is how these structural patterns relate to symptoms, organ involvement, or response to therapy. [24]